Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.51 |
| ▸ | PPARA | Q07869 | 9/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 8/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11993021 | 1.00 | PPARG (0.51) | PPARGPPARAPTPN1PPARDPTGES | |
| SCHEMBL6903473 | 0.92 | PPARG (0.44) | PPARGPPARAPTPN1PPARD | |
| SCHEMBL3973021 | 0.89 | PPARG (0.47) | PPARGPPARAPPARDALOX5 | |
| SCHEMBL3967738 | 0.87 | PPARG (0.62) | PPARGPPARAPTPN1SLC6A9 | |
| SCHEMBL3973311 | 0.87 | PPARG (0.54) | PPARGPPARAPTPN1 | |
| SCHEMBL3971145 | 0.86 | PPARA (0.52) | PPARGPPARAPTPN1PPARDPTGES | |
| SCHEMBL3971738 | 0.86 | PPARA (0.52) | PPARGPPARAPTPN1PPARDPTGES | |
| SCHEMBL3973894 | 0.86 | PPARA (0.52) | PPARGPPARAPTPN1PPARDPTGES | |
| Pemaglitazar SCHEMBL6902223 | 0.83 | PPARA (0.52) | PPARGPPARAPTPN1PPARDSLC6A9 | |
| Pemaglitazar SCHEMBL6902218 | 0.83 | PPARA (0.52) | PPARGPPARAPTPN1PPARDSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491747-B2 | 4-(Arylthio)- or (4-heteroarylthio)butyric acid derivatives that may be used in the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-20050020651-A1 | Butyric acid derivatives | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020651-A1 | Butyric acid derivatives | GPR119, DBI, GABRB1 | PPARG 492/4885PPARA 425/4885PTPN1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.